SCHEMBL17439308

SCHEMBL17439308

CC(=O)N(C)c1cc(B2OC(C)(C)C(C)(C)O2)ccn1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.34
HIF1A Q16665 3/20 0.34
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
PDGFRB P09619 1/20 0.34
KDR P35968 1/20 0.34
LIPG Q9Y5X9 7/20 0.33
LPL P06858 6/20 0.33
P4HB P07237 1/20 0.33
ROCK1 Q13464 1/20 0.33
F2 P00734 1/20 0.33
F11 P03951 1/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
CA9 Q16790 2/20 0.32
CA12 O43570 1/20 0.32
CA3 P07451 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3476749 0.89 LIPG (0.36) DGAT1HIF1AGSK3AGSK3BPDGFRB
SCHEMBL29845293 0.82 BACE1 (0.44) DGAT1HIF1AGSK3AGSK3BPDGFRB
SCHEMBL25146980 0.82 BACE1 (0.44) DGAT1HIF1AGSK3AGSK3BPDGFRB
SCHEMBL14804515 0.82 LPL (0.39) LIPGLPLF11CA1CA2
Hydrochloric Acid SCHEMBL16109917 0.81 LPL (0.38) LIPGLPLF11CA1CA2
SCHEMBL1554613 0.78 LIPG (0.39) DGAT1HIF1AGSK3AGSK3BPDGFRB
SCHEMBL1554719 0.77 DGAT1 (0.37) DGAT1HIF1AGSK3AGSK3BPDGFRB
SCHEMBL2067392 0.77 LPL (0.35) LIPGLPLCA1CA2CA9
SCHEMBL22685876 0.77 ALDH1A1 (0.40) DGAT1HIF1AGSK3AGSK3BPDGFRB
SCHEMBL29504593 0.77 ALDH1A1 (0.40) DGAT1HIF1AGSK3AGSK3BPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970323-B1 FUROPYRIDINES AS BROMODOMAIN INHIBITORS. GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD (GB) 2017-10-18 EP disclosed
US-9670221-B2 Furopyridines as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2017-06-06 US disclosed
US-9670221-B2 Furopyridines as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2017-06-06 US disclosed
US-9670221-B2 Furopyridines as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2017-06-06 US disclosed
US-9663533-B2 Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors GLAXOSMITHKLINE LLC (US) 2017-05-30 US disclosed
EP-2920183-B1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS GLAXOSMITHKLINE LLC (US) 2017-03-08 EP disclosed
US-20160297832-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS GLAXOSMITHKLINE LLC 2016-10-13 US disclosed
US-20160016966-A1 FUROPYRIDINES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-01-21 US disclosed
US-20160016966-A1 FUROPYRIDINES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-01-21 US disclosed
US-20160016966-A1 FUROPYRIDINES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297832-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS BRD4, BET1, BRD3 DGAT1 4220/4885HIF1A 4025/4885GSK3A 1042/4885
US-20160016966-A1 FUROPYRIDINES AS BROMODOMAIN INHIBITORS BRD3, BRD4, BRPF3 DGAT1 1755/4885HIF1A 4280/4885GSK3A 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.